To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
With the on-going relentless efforts to imbibe new developments in ART, India will make significant progress in ensuring the best facilities and care for fertility to couples in India
A pharma industry veteran with over three decades of experience in domestic as well as international markets
_256_384.jpg)
The company is proud to be at the forefront of promoting cancer awareness and hopes to make a positive impact on the lives of its employees
_256_384.jpg)
Through this important initiative, Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in the Aptivate Champion Run
Subscribe To Our Newsletter & Stay Updated
